Glaxosmithkline Pharmaceuticals is currently trading at Rs 2117.85, up by 28.75 points or 1.38% from its previous closing of Rs. 2089.10 on the BSE.
The scrip opened at Rs 2089.90 and has touched a high and low of Rs 2117.90 and Rs 2054.60 respectively. So far 1079 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 10 has touched a 52 week high of Rs 2475.00 on 14-Jun-2011 and a 52 week low of Rs 1905.00 on 26-Nov-2010.
Last one week high and low of the scrip stood at Rs 2117.90 and Rs 1966.05 respectively. The current market cap of the company is Rs 17695.31 crore.
The promoters holding in the company stood at 50.67% while Institutions and Non-Institutions held 32.66% and 16.67% respectively.
Recently, pharma major, GlaxoSmithKline Pharmaceuticals was reported to be actively looking at in-licensing deals with global MNCs. The reports stated that the company is currently in negotiation of in-liscensing deals with 3 parties for deals in Derma, Respiratory & Antibiotic areas.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1680.10 |
| Dr. Reddys Lab | 1222.90 |
| Cipla | 1239.65 |
| Zydus Lifesciences | 945.05 |
| Lupin | 2320.10 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: